<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57293">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02360215</url>
  </required_header>
  <id_info>
    <org_study_id>NRG-CC001</org_study_id>
    <secondary_id>NCI-2015-00030</secondary_id>
    <secondary_id>NRG-CC001</secondary_id>
    <secondary_id>NRG-CC001</secondary_id>
    <secondary_id>NRG-CC001</secondary_id>
    <secondary_id>UG1CA189867</secondary_id>
    <nct_id>NCT02360215</nct_id>
  </id_info>
  <brief_title>Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases</brief_title>
  <official_title>A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NRG Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial compares memantine hydrochloride and whole-brain
      radiotherapy with or without hippocampal avoidance in reducing neurocognitive decline in
      patients with cancer that has spread from the primary site (place where it started) to the
      brain. Whole brain radiotherapy (WBRT) is the most common treatment for brain metastasis.
      Unfortunately, the majority of patients with brain metastases experience cognitive (such as
      learning and memory) deterioration after WBRT. Memantine hydrochloride may enhance cognitive
      function by binding to and inhibiting channels of receptors located in the central nervous
      system. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
      Using radiation techniques, such as intensity modulated radiotherapy to avoid the
      hippocampal region during WBRT, may reduce the radiation dose to the hippocampus and help
      limit the radiation-induced cognitive decline. It is not yet known whether giving memantine
      hydrochloride and WBRT with or without hippocampal avoidance works better in reducing
      neurocognitive decline in patients with brain metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine whether the addition of whole-brain radiotherapy with hippocampal avoidance
      (HA-WBRT) increases time to neurocognitive failure at months 2, 4, 6, and 12 as measured by
      neurocognitive decline on a battery of tests: the Hopkins Verbal Learning Test-Revised
      (HVLT-R) for Total Recall, Delayed Recall, and Delayed Recognition, Controlled Oral Word
      Association (COWA), and the Trail Making Test (TMT) Parts A and B.

      SECONDARY OBJECTIVES:

      I. Determine whether the addition of HA-WBRT preserves neurocognitive function at months 2,
      4, 6, and 12 as separately measured by each test, the HVLT-R for Total Recall, Delayed
      Recall, and Delayed Recognition; COWA; and TMT Parts A and B.

      II. Evaluate the potential benefit of HA-WBRT in symptom burden, as measured by the M. D.
      Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT).

      III. Assessment of quality adjusted survival and cost analysis using the five-level version
      of the EuroQol five-dimensional (EQ-5D-5L).

      IV. Compare cumulative incidence of progression and overall survival after WBRT versus
      HA-WBRT.

      V. Compare adverse events between the treatment arms according to the Common Terminology
      Criteria for Adverse Events (CTCAE) version (v)4.0 criteria.

      TERTIARY OBJECTIVES:

      I. Collect serum, plasma, and imaging studies for future translational research analyses.

      II. Evaluate magnetic resonance (MR) imaging biomarkers of white matter injury and
      hippocampal volumetry at baseline and 6 months as potential predictors of neurocognitive
      decline and differential benefit from HA-WBRT as compared to WBRT.

      III. Association of symptom burden and anxiety/depression with neurocognitive function.

      IV. Evaluate the potential correlation between the prognostic scoring systems Radiation
      Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) and the
      diagnosis-specific graded prognostic assessment (DS-GPA) and neurocognitive function at
      baseline and overtime.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive memantine hydrochloride orally (PO) twice daily (BID) for 24 weeks.
      Patients undergo WBRT daily over approximately 2 weeks (10 fractions).

      ARM II: Patients receive memantine hydrochloride as in Arm I. Patients undergo HA-WBRT using
      intensity modulated radiation therapy (IMRT) daily over approximately 2 weeks (10
      fractions).

      After completion of study treatment, patients are followed up at 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to neurocognitive failure, as measured by neurocognitive decline on HVLT-R, COWA, and TMT Parts A and B</measure>
    <time_frame>At 6 months</time_frame>
    <description>The cumulative incidence approach will be used to estimate the median time to neurocognitive failure to account for the competing risk of death. Gray's test will be used to test for statistically significant difference in the distribution of neurocognitive failure times. The cause-specific Cox proportional hazards regression model will be used to evaluate the effect of stratification variables (RPA class and prior therapy) and other baseline characteristics, such as Karnofsky performance score, DS-GPA grade, FLAIR volume change, and hippocampal volume, on time to neurocognitive decline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health outcomes, as measured by the EQ-5D-5L</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The 5-item utility score in EQ-5D-5L will be used for the cost-utility analysis. The Z-test will be used to test the hypothesis that the cost-utility in the 2 treatment arms is the same at 6 months after initiation of treatment with a significance level of 0.05 and a 2-sided test. The remaining time points in which the EQ-5D-5L is collected also will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AE) as measured by CTCAE v4.0</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Counts of all AEs by grade will be provided by treatment arm. Counts and frequencies will be provided for the worst grade AE experienced by the patient by treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial progression defined as progression in the brain or death</measure>
    <time_frame>At 6 months</time_frame>
    <description>MRI scans at baseline and 6 months will be reviewed to determine intracranial progression centrally. The 6 month comparison in intracranial progression rates between the treatment arms will be compared using a test of proportions. It is expected that the rates will be similar in both treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of randomization to the date of death, or, otherwise, the last follow-up date on which the patient was reported alive, assessed up to 12 months</time_frame>
    <description>Estimated using the Kaplan-Meier method, and differences between treatment arms will be tested using the log rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preservation of neurocognitive function, as measured by neurocognitive decline on HVLT-R, COWA, and TMT Parts A and B, and Clinical Trial Battery Composite (CTB COMP) score</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Compared between treatment arms at each follow-up time point using Fisher's exact test. A mixed effects model will be used to assess changes of standardized neurocognitive scores across time using all available data while adjusting for stratification variables and other baseline characteristics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom burden, as measured by the MDASI-BT</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Four subscales (symptom severity, symptom interference, neurologic factor, and cognitive factor score) as well as certain individual items (fatigue, neurologic factor items, and cognitive factor items) of the MDASI-BT will be analyzed. For discrete time point analyses, the change from baseline to each follow-up time point (2, 4, 6, and 12 months from the start of treatment) will be calculated and compared between treatment arms using a t-test or Wilcoxon-Mann-Whitney test, depending on the normality of the data. Mixed effects models will be used to assess changes of the four subscale scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to intracranial progression</measure>
    <time_frame>From the date of randomization to the date of intracranial progression, death, or, otherwise, the last follow-up date on which the patient was reported alive, assessed up to 12 months</time_frame>
    <description>Estimated using the Kaplan-Meier method, and differences between treatment arms will be tested using the log rank test.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anxiety/depression measured using the EQ-5D-5L</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>An exploratory analysis, beginning with correlation coefficients, will be used to assess the association of symptom burden and anxiety/depression with neurocognitive function at each time point. The symptom burden items of interest are the &quot;distressed (upset)&quot;, &quot;sad&quot;, and &quot;mood&quot; items. From the EQ-5D-5L, the depression/anxiety item will be of interest.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of RTOG RPA and the diagnosis-specific graded prognostic assessment (DSGPA) on neurocognitive function</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Neurocognitive function, as measured by the HVLT-R, COWA, and TMT, will be correlated with both the RTOG RPA and the DS-GPA classification systems. Baseline neurocognitive function for each test will be compared between both RPA classes using either a t-test or Wilcoxon-Mann-Whitney test, depending on the normality of the data.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of white matter injury and hippocampal volume on neurocognitive function</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Evaluated through MRI scans using physician-contoured and auto-contoured scores. Concordance rates will be assessed using Kappa statistics. The auto-contoured scores will be used for the remaining analyses due to the number of physicians reviewing the scans. White matter injury is measured by FLAIR volume change and is a continuous variable. Hippocampal volume is measured as a continuous variable also and both will be covariates considered in the Cox proportional hazards model to assess the impact on time to neurocognitive failure and the longitudinal modeling of neurocognitive function.</description>
  </other_outcome>
  <other_outcome>
    <measure>MDASI-BT mood variables</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The relationship between EQ-5D-5L and MDASI-BT mood variables and neurocognitive function will be assessed.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Cognitive Impairment</condition>
  <condition>Metastatic Malignant Neoplasm in the Brain</condition>
  <condition>Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (memantine hydrochloride, WBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive memantine hydrochloride PO BID for 24 weeks. Patients undergo WBRT daily over approximately 2 weeks (10 fractions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (memantine hydrochloride, HA-WBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive memantine hydrochloride as in Arm I. Patients undergo HA-WBRT using IMRT daily over approximately 2 weeks (10 fractions).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (memantine hydrochloride, WBRT)</arm_group_label>
    <arm_group_label>Arm II (memantine hydrochloride, HA-WBRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo HA-WBRT using IMRT</description>
    <arm_group_label>Arm II (memantine hydrochloride, HA-WBRT)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (memantine hydrochloride, WBRT)</arm_group_label>
    <arm_group_label>Arm II (memantine hydrochloride, HA-WBRT)</arm_group_label>
    <other_name>Ebixia</other_name>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (memantine hydrochloride, WBRT)</arm_group_label>
    <arm_group_label>Arm II (memantine hydrochloride, HA-WBRT)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole-Brain Radiotherapy</intervention_name>
    <description>Undergo WBRT</description>
    <arm_group_label>Arm I (memantine hydrochloride, WBRT)</arm_group_label>
    <other_name>WBRT</other_name>
    <other_name>whole-brain radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole-Brain Radiotherapy</intervention_name>
    <description>Undergo HA-WBRT using IMRT</description>
    <arm_group_label>Arm II (memantine hydrochloride, HA-WBRT)</arm_group_label>
    <other_name>WBRT</other_name>
    <other_name>whole-brain radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PRIOR TO STEP 1 REGISTRATION:

          -  Brain metastases outside a 5-mm margin around either hippocampus must be visible on
             contrast-enhanced magnetic resonance imaging (MRI) performed =&lt; 21 days prior to Step
             1 registration; an allowed exception, regarding ability to image brain metastases,
             would be that patients who had undergone radiosurgery or surgical resection and are
             planning adjuvant WBRT do not have to have visible disease but do need a pre-surgery
             MRI or computed tomography (CT) scan demonstrating brain metastases; however, the
             brain metastases could not have been within 5 mm of either hippocampus

          -  Patients must have a gadolinium contrast-enhanced three-dimensional spoiled gradient
             (SPGR), magnetization-prepared rapid gradient echo (MP-RAGE), or turbo field echo
             (TFE) axial MRI scan with standard axial and coronal gadolinium contrast-enhanced
             T1-weighted sequence and axial T2/FLAIR sequence acquisitions; to yield acceptable
             image quality, the gadolinium contrast-enhanced three-dimensional SPGR, MP-RAGE, or
             TFE axial MRI scan should use the smallest possible axial slice thickness not
             exceeding 1.5 mm; the associated coronal and sagittal contrast-enhanced T1 sequences
             can be up to 2.5 mm in slice thickness; this MRI must be obtained =&lt; 21 days prior to
             step 1 registration; the vendor specific MRI protocols are available for download
             from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

          -  Patients must provide study-specific informed consent prior to registration

          -  PRIOR TO STEP 2 REGISTRATION:

          -  The following baseline neurocognitive assessments must be completed prior to Step 2
             registration: HVLT-R, TMT, and COWA; the neurocognitive assessment will be uploaded
             into the NRG RAVE System for evaluation by Dr. Wefel; once the upload is complete, a
             notification will be sent to proceed to Step 2; NOTE: completed baseline
             neurocognitive assessments can be uploaded at the time of Step 1 registration

          -  Pathologically (histologically or cytologically) proven diagnosis of solid tumor
             malignancy within 5 years prior to Step 2 registration

          -  History and physical examination within 28 days prior to Step 2 registration

          -  Karnofsky performance status of &gt;= 70 within 28 days prior to Step 2 registration

          -  Serum creatinine =&lt; 3 mg/dL (265 umol/L) and creatinine clearance &gt;= 30 ml/min

          -  Blood urea nitrogen (BUN) within institutional upper limit of normal (e.g. &lt; 20
             mg/dL)

          -  Total bilirubin =&lt; 2.5 mg/dL (43 umol/L)

          -  Patients may have had prior therapy for brain metastasis, including radiosurgery and
             surgical resection; patients must have completed prior therapy by at least 14 days
             prior to Step 2 for surgical resection and 7 days for radiosurgery

          -  Negative serum pregnancy test (in women of childbearing potential) =&lt; 14 days prior
             to Step 2; women of childbearing potential and men who are sexually active must
             practice adequate contraception while on study

          -  Patients who are primary English or French speakers are eligible

        Exclusion Criteria:

          -  Prior external beam radiation therapy to the brain or whole brain radiation therapy

          -  Planned cytotoxic chemotherapy during the WBRT only; patients may have had prior
             chemotherapy

          -  Radiographic evidence of hydrocephalus or other architectural distortion of the
             ventricular system, including placement of external ventricular drain or
             ventriculoperitoneal shunt

          -  Severe, active co-morbidity defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months

               -  Transmural myocardial infarction within the last 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the
                  time of registration

               -  Chronic obstructive pulmonary disease exacerbation or other acute respiratory
                  illness precluding study therapy at the time of registration

               -  Severe hepatic disease defined as a diagnosis of Child-Pugh class B or C hepatic
                  disease

               -  Renal tubular acidosis or metabolic acidosis

               -  Human immunodeficiency virus (HIV) positive with cluster of differentiation
                  (CD)4 count &lt; 200 cells/microliter; note that patients who are HIV positive are
                  eligible, provided they are under treatment with highly active antiretroviral
                  therapy (HAART) and have a CD4 count &gt;= 200 cells/microliter within 30 days
                  prior to registration; Note also that HIV testing is not required for
                  eligibility for this protocol

          -  Pregnant or lactating women, or women of childbearing potential and men who are
             sexually active and not willing/able to use medically acceptable forms of
             contraception

          -  Prior allergic reaction to memantine (memantine hydrochloride)

          -  Current alcohol or drug abuse (may exacerbate lethargy/dizziness with memantine)

          -  Intractable seizures while on adequate anticonvulsant therapyâ€”more than 1 seizure per
             month for the past 2 months

          -  Patients with definitive leptomeningeal metastases

          -  Patients with brain metastases from primary germ cell tumors, small cell carcinoma,
             unknown primary, or lymphoma

          -  Contraindication to magnetic resonance (MR) imaging such as implanted metal devices
             or foreign bodies

          -  Contraindication to gadolinium contrast administration during MR imaging, such as
             allergy or insufficient renal function

          -  Current use of (other N-methyl D-aspartate [NMDA] antagonists) amantadine, ketamine,
             or dextromethorphan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Brown</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Li</last_name>
      <phone>713-563-2331</phone>
      <email>jing.li@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jing Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Arizona Medical Center-University Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baldassarre (. Stea</last_name>
      <phone>520-626-9008</phone>
    </contact>
    <investigator>
      <last_name>Baldassarre (. Stea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland-Broadway</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott G. Soltys</last_name>
      <phone>650-725-8231</phone>
      <email>clinicaltrials@med.stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Scott G. Soltys</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Rancho Cordova Cancer Center</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Centers Radiation Oncology Services-Roseville</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Permanente Medical Group-Roseville Radiation Oncology</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95678</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Sutter General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>916-454-6618</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jona A. Hattangadi-Gluth</last_name>
      <email>cancercto@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Jona A. Hattangadi-Gluth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>408-851-8010</phone>
      <email>samantha.seaward@kp.org</email>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keren Sturtz</last_name>
      <phone>303-777-2642</phone>
      <email>kgeisen@co-cancerresearch.org</email>
    </contact>
    <investigator>
      <last_name>Keren Sturtz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Medical Center</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas A. Blondin</last_name>
      <phone>203-581-6587</phone>
      <email>nblondin@anscneuro.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas A. Blondin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System-Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory A. Masters</last_name>
      <phone>302-366-1700</phone>
      <email>gmasters@cbg.org</email>
    </contact>
    <investigator>
      <last_name>Gregory A. Masters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic-Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin S. Murphy</last_name>
      <phone>866-223-8100</phone>
      <email>murphye3@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Erin S. Murphy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam W. Nowlan</last_name>
      <phone>770-916-4434</phone>
      <email>ORS@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Adam W. Nowlan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron W. Pederson</last_name>
      <phone>912-350-8819</phone>
      <email>aaronpederson@memorialhealth.com</email>
    </contact>
    <investigator>
      <last_name>Aaron W. Pederson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Alphonsus Cancer Care Center-Boise</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-4673</phone>
      <email>samir.narayan@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul G. Montgomery</last_name>
      <phone>208-381-3124</phone>
      <email>montgomp@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Paul G. Montgomery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mountain States Tumor Institute-Twin Falls</name>
      <address>
        <city>Twin Falls</city>
        <state>Idaho</state>
        <zip>83301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul G. Montgomery</last_name>
      <phone>208-381-3124</phone>
      <email>montgomp@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Paul G. Montgomery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy J. Kruser</last_name>
      <phone>312-926-6374</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy J. Kruser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Chmura</last_name>
      <phone>773-834-7233</phone>
      <email>schmura@radonc.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Steven J. Chmura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-6606</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center Delnor</name>
      <address>
        <city>Geneva</city>
        <state>Illinois</state>
        <zip>60134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinai Gondi</last_name>
      <phone>630-352-5489</phone>
      <email>Claudine.Gamster@CadenceHealth.org</email>
    </contact>
    <investigator>
      <last_name>Vinai Gondi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhishek A. Solanki</last_name>
      <phone>708-216-4498</phone>
      <email>abhishek.solanki@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>Abhishek A. Solanki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSF Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-6606</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center Warrenville</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinai Gondi</last_name>
      <phone>630-352-5489</phone>
      <email>Claudine.Gamster@CadenceHealth.org</email>
    </contact>
    <investigator>
      <last_name>Vinai Gondi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Hospital Randallia</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian K. Chang</last_name>
      <phone>260-266-9130</phone>
      <email>parkviewresearch@parkview.com</email>
    </contact>
    <investigator>
      <last_name>Brian K. Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parvesh Kumar</last_name>
      <phone>913-588-3663</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Parvesh Kumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaker R. Dakhil</last_name>
      <phone>316-262-0706</phone>
      <email>shaker.dakhil@cancercenterofkansas.com</email>
    </contact>
    <investigator>
      <last_name>Shaker R. Dakhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald C. McGarry</last_name>
      <phone>859-257-7483</phone>
      <email>ronald.mcgarry@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald C. McGarry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Feigenberg</last_name>
      <phone>410-328-5279</phone>
      <email>sfeigenberg@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Steven J. Feigenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upper Chesapeake Medical Center</name>
      <address>
        <city>Bel Air</city>
        <state>Maryland</state>
        <zip>21014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark V. Mishra</last_name>
      <phone>410-328-6911</phone>
      <email>mmishra@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Mark V. Mishra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John E. Mignano</last_name>
      <phone>617-636-4513</phone>
      <email>ContactUsCancerCenter@TuftsMedicalCenter.org</email>
    </contact>
    <investigator>
      <last_name>John E. Mignano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaudia U. Hunter</last_name>
      <phone>978-937-6835</phone>
      <email>ghincks@lowellgeneral.org</email>
    </contact>
    <investigator>
      <last_name>Klaudia U. Hunter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lowell General Hospital</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew S. Katz</last_name>
      <phone>978-937-7962</phone>
      <email>ghincks@lowellgeneral.org</email>
    </contact>
    <investigator>
      <last_name>Matthew S. Katz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-5344</phone>
      <email>samir.narayan@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology-Clarkston</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank A. Vicini</last_name>
      <phone>888-326-9729</phone>
    </contact>
    <investigator>
      <last_name>Frank A. Vicini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor M. Walker</last_name>
      <phone>313-916-1266</phone>
      <email>ewalker1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Eleanor M. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology-Farmington Hills</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank A. Vicini</last_name>
      <phone>888-326-9729</phone>
    </contact>
    <investigator>
      <last_name>Frank A. Vicini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute-Flint</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Devisetty</last_name>
      <phone>989-667-6257</phone>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute-Macomb</name>
      <address>
        <city>Mount Clemens</city>
        <state>Michigan</state>
        <zip>48043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Devisetty</last_name>
      <phone>989-667-6257</phone>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute-Owosso</name>
      <address>
        <city>Owosso</city>
        <state>Michigan</state>
        <zip>48867</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Devisetty</last_name>
      <phone>989-667-6257</phone>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute-Northern Michigan</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Devisetty</last_name>
      <phone>989-667-6257</phone>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeland Hospital</name>
      <address>
        <city>St. Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen J. Yost</last_name>
      <phone>616-954-2116</phone>
      <email>connie.szczepanek@grcop.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology-Troy</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank A. Vicini</last_name>
      <phone>888-326-9729</phone>
    </contact>
    <investigator>
      <last_name>Frank A. Vicini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center - West Bloomfield</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor M. Walker</last_name>
      <phone>313-916-1266</phone>
      <email>ewalker1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Eleanor M. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph W. Leach</last_name>
      <phone>952-993-1550</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Joseph W. Leach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia N. Laack</last_name>
      <phone>507-284-0079</phone>
      <email>laack.nadia@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Nadia N. Laack</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish West County Hospital</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clifford G. Robinson</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Clifford G. Robinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Kansas City Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parvesh Kumar</last_name>
      <phone>913-588-3663</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Parvesh Kumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clifford G. Robinson</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Clifford G. Robinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>kcheek@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - Saint Peters</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clifford G. Robinson</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Clifford G. Robinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Billings Clinic Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>406-237-5470</phone>
      <email>bmarchello@mtcancer.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benefis Healthcare- Sletten Cancer Institute</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
      <email>bmarchello@mtcancer.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew O. Wahl</last_name>
      <phone>402-552-3926</phone>
      <email>unmcrsa@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew O. Wahl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan C. Hartford</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>Alan C. Hartford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William R. Bodner</last_name>
      <phone>718-405-8230</phone>
      <email>aecc@aecom.yu.edu</email>
    </contact>
    <investigator>
      <last_name>William R. Bodner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The New York Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sameer Rafla-Demetrious</last_name>
      <phone>718-780-3637</phone>
      <email>srafla@verizon.net</email>
    </contact>
    <investigator>
      <last_name>Sameer Rafla-Demetrious</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhchyau Chen</last_name>
      <phone>585-275-5830</phone>
    </contact>
    <investigator>
      <last_name>Yuhchyau Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Radiation Oncology</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A. Papagikos</last_name>
      <phone>910-251-8286</phone>
      <email>mpapagikos@ccradonc.com</email>
    </contact>
    <investigator>
      <last_name>Michael A. Papagikos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roger Maris Cancer Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>701-234-6444</phone>
      <email>preston.steen@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center/Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin S. Murphy</last_name>
      <phone>866-223-8100</phone>
      <email>murphye3@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Erin S. Murphy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin S. Murphy</last_name>
      <phone>216-445-1068</phone>
      <email>murphye3@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Erin S. Murphy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan J. Wuthrick</last_name>
      <phone>614-293-4044</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Evan J. Wuthrick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center Independence</name>
      <address>
        <city>Independence</city>
        <state>Ohio</state>
        <zip>44131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin S. Murphy</last_name>
      <phone>216-445-1068</phone>
      <email>murphye3@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Erin S. Murphy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center Strongsville</name>
      <address>
        <city>Strongsville</city>
        <state>Ohio</state>
        <zip>44136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin S. Murphy</last_name>
      <phone>216-445-1068</phone>
      <email>murphye3@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Erin S. Murphy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence S. Herman</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Terence S. Herman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan Hospital and Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Y. Kee</last_name>
      <phone>503-413-8363</phone>
      <email>cancer@lhs.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Y. Kee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne H. Pinover</last_name>
      <phone>215-481-6741</phone>
      <email>wpinover@amh.org</email>
    </contact>
    <investigator>
      <last_name>Wayne H. Pinover</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Hospital</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert S. DeNittis</last_name>
      <phone>484-476-3595</phone>
      <email>ewend@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Albert S. DeNittis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NRG Oncology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul D. Brown</last_name>
      <phone>713-563-2415</phone>
      <email>pdbrown@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Paul D. Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenyin Shi</last_name>
      <phone>215-503-0013</phone>
      <email>wenyin.shi@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Wenyin Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aria Health-Torresdale Campus</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenyin Shi</last_name>
      <phone>215-955-6084</phone>
      <email>wenyin.shi@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Wenyin Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reading Hospital</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrence P. Cescon</last_name>
      <phone>610-988-9323</phone>
      <email>terrence.cescon@readinghealth.org</email>
    </contact>
    <investigator>
      <last_name>Terrence P. Cescon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau Medical Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert S. DeNittis</last_name>
      <phone>484-476-3595</phone>
      <email>ewend@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Albert S. DeNittis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L. Grisell</last_name>
      <phone>864-679-4001</phone>
      <email>dgrisell@ghs.org</email>
    </contact>
    <investigator>
      <last_name>David L. Grisell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L. Grisell</last_name>
      <phone>864-679-4001</phone>
      <email>dgrisell@ghs.org</email>
    </contact>
    <investigator>
      <last_name>David L. Grisell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Self Regional Healthcare</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph M. Jenrette</last_name>
      <phone>843-792-5498</phone>
      <email>jenretbm@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph M. Jenrette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L. Grisell</last_name>
      <phone>864-679-4001</phone>
      <email>dgrisell@ghs.org</email>
    </contact>
    <investigator>
      <last_name>David L. Grisell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>701-234-6444</phone>
      <email>preston.steen@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Attia</last_name>
      <phone>800-811-8480</phone>
      <email>albert.attia@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Albert Attia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0565</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd A. Swanson</last_name>
      <phone>409-747-0064</phone>
      <email>clinical.research@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>Todd A. Swanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Li</last_name>
      <phone>713-563-2331</phone>
      <email>jing.li@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jing Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UTMB Cancer Center at Victory Lakes</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd A. Swanson</last_name>
      <phone>409-747-0064</phone>
      <email>clinical.research@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>Todd A. Swanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Healthcare</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm D. Mattes</last_name>
      <phone>304-581-1151</phone>
      <email>sfilburn@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Malcolm D. Mattes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wheeling Hospital/Schiffler Cancer Center</name>
      <address>
        <city>Wheeling</city>
        <state>West Virginia</state>
        <zip>26003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jondavid Pollock</last_name>
      <phone>304-243-6442</phone>
    </contact>
    <investigator>
      <last_name>Jondavid Pollock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora BayCare Medical Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54311-6519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen L. Ziaja</last_name>
      <phone>414-649-5309</phone>
      <email>ellen.ziaja@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Ellen L. Ziaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven P. Howard</last_name>
      <phone>608-263-9947</phone>
      <email>howard@humonc.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Steven P. Howard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Memorial Hospital</name>
      <address>
        <city>Menomonee Falls</city>
        <state>Wisconsin</state>
        <zip>53051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph A. Bovi</last_name>
      <phone>414-805-4380</phone>
    </contact>
    <investigator>
      <last_name>Joseph A. Bovi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Saint Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen L. Ziaja</last_name>
      <phone>414-649-5309</phone>
      <email>ellen.ziaja@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Ellen L. Ziaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph A. Bovi</last_name>
      <phone>414-805-4380</phone>
    </contact>
    <investigator>
      <last_name>Joseph A. Bovi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zablocki Veterans Administration Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth M. Gore</last_name>
      <phone>414-805-4380</phone>
      <email>egore@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth M. Gore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vince Lombardi Cancer Clinic - Oshkosh</name>
      <address>
        <city>Oshkosh</city>
        <state>Wisconsin</state>
        <zip>54904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen L. Ziaja</last_name>
      <phone>800-252-2990</phone>
      <email>ellen.ziaja@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Ellen L. Ziaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Medical Center in Summit</name>
      <address>
        <city>Summit</city>
        <state>Wisconsin</state>
        <zip>53066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen L. Ziaja</last_name>
      <phone>414-649-5309</phone>
      <email>ellen.ziaja@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Ellen L. Ziaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora West Allis Medical Center</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen L. Ziaja</last_name>
      <phone>414-649-5309</phone>
      <email>ellen.ziaja@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Ellen L. Ziaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aspirus UW Cancer Center</name>
      <address>
        <city>Wisconsin Rapids</city>
        <state>Wisconsin</state>
        <zip>54494</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darryl R. Barton</last_name>
      <phone>877-405-6866</phone>
      <email>darryl.barton@aspirus.org</email>
    </contact>
    <investigator>
      <last_name>Darryl R. Barton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Roberge</last_name>
      <phone>514-412-7537</phone>
      <email>sylvie.beaudoin.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>David Roberge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Roberge</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>23611</phone_ext>
      <email>sylvie.beaudoin.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>David Roberge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke-Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Roberge</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>23611</phone_ext>
      <email>sylvie.beaudoin.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>David Roberge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle J. Ferguson</last_name>
      <phone>306-766-2213</phone>
      <email>michelle.ferguson@saskcancer.ca</email>
    </contact>
    <investigator>
      <last_name>Michelle J. Ferguson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijayananda Kundapur</last_name>
      <phone>306-655-2910</phone>
      <email>vijayananda.kundapur@saskcancer.ca</email>
    </contact>
    <investigator>
      <last_name>Vijayananda Kundapur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 17, 2016</lastchanged_date>
  <firstreceived_date>February 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
